Tier 2 — strong

Effect of betaine supplementation on plasma nitrate/nitrite in exercise-trained men

Richard J Bloomer, Tyler M Farney, John F Trepanowski, Cameron G McCarthy, Robert E Canale
Journal of the International Society of Sports Nutrition 2011 8:5

Bibliography

PubMed
PMID 21414230
PubMed Central
PMC3066115
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
Reported disclosure: Competing interestsRJB has received research funding or acted as consultant to nutraceutical and dietary supplement companies. All other authors declare no competing interests.

Study snapshot

DesignAcute and short-term intervention studies
ModelHuman participants
SampleExercise-trained men in three protocols
InterventionAcute betaine 1.25-6 g; repeated 2.5-6 g/day protocols
DurationAcute sampling and 7-14 day supplementation
EndpointsNitrate and nitrite; Nitric-oxide hypothesis

What the study showed, in plain terms

Published in 2011, this source examined exercise performance and body composition. Design: Acute and short-term intervention studies. Sample/model: Exercise-trained men in three protocols. The exposure or intervention was Acute betaine 1.25-6 g; repeated 2.5-6 g/day protocols. Follow-up or treatment period: Acute sampling and 7-14 day supplementation.

None of the tested protocols produced a significant rise in circulating nitrate/nitrite.

Different small protocols with an indirect nitric-oxide marker; other mechanisms remain possible.

Continue with TMG Data Center

Continue with Betaine Anhydrous Pre-Workout: Performance, Dose and Evidence

Key findings

  • None of the tested protocols produced a significant rise in circulating nitrate/nitrite.
  • The recorded outcome domains were Nitrate and nitrite; Nitric-oxide hypothesis.
  • The result applies to the tested exposure: Acute betaine 1.25-6 g; repeated 2.5-6 g/day protocols; Acute sampling and 7-14 day supplementation.

What this study can and cannot tell us

  • Different small protocols with an indirect nitric-oxide marker; other mechanisms remain possible.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified